Intermedin1-53 attenuates vascular calcification in rats with chronic kidney disease by upregulation of α-Klotho

Kidney Int. 2016 Mar;89(3):586-600. doi: 10.1016/j.kint.2015.12.029. Epub 2016 Jan 28.

Abstract

Deficiency in α-Klotho is involved in the pathogenesis of vascular calcification. Since intermedin (IMD)1-53 (a calcitonin/calcitonin gene-related peptide) protects against vascular calcification, we studied whether IMD1-53 inhibits vascular calcification by upregulating α-Klotho. A rat model of chronic kidney disease (CKD) with vascular calcification induced by the 5/6 nephrectomy plus vitamin D3 was used for study. The aortas of rats with CKD showed reduced IMD content but an increase of its receptor, calcitonin receptor-like receptor, and its receptor modifier, receptor activity-modifying protein 3. IMD1-53 treatment reduced vascular calcification. The expression of α-Klotho was greatly decreased in the aortas of rats with CKD but increased in the aortas of IMD1-53-treated rats with CKD. In vitro, IMD1-53 increased α-Klotho protein level in calcified vascular smooth muscle cells. α-Klotho knockdown blocked the inhibitory effect of IMD1-53 on vascular smooth muscle cell calcification and their transformation into osteoblast-like cells. The effect of IMD1-53 to upregulate α-Klotho and inhibit vascular smooth muscle cell calcification was abolished by knockdown of its receptor or its modifier protein, or treatment with the protein kinase A inhibitor H89. Thus, IMD1-53 may attenuate vascular calcification by upregulating α-Klotho via the calcitonin receptor/modifying protein complex and protein kinase A signaling.

Keywords: calcitonin receptor-like receptor; chronic kidney disease; intermedin(1-53); vascular calcification; α-Klotho.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism
  • Aorta, Thoracic / pathology
  • Cell Transdifferentiation / drug effects*
  • Cells, Cultured
  • Cholecalciferol
  • Cyclic AMP / metabolism
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Disease Models, Animal
  • Glucuronidase / genetics
  • Glucuronidase / metabolism*
  • Humans
  • Klotho Proteins
  • Male
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Muscle, Smooth, Vascular / pathology
  • Myocytes, Smooth Muscle / drug effects*
  • Myocytes, Smooth Muscle / metabolism
  • Myocytes, Smooth Muscle / pathology
  • Nephrectomy
  • Osteoblasts / drug effects*
  • Osteoblasts / metabolism
  • Osteoblasts / pathology
  • Peptide Hormones / pharmacology*
  • Phenotype
  • RNA Interference
  • Rats, Sprague-Dawley
  • Receptor Activity-Modifying Protein 3 / metabolism
  • Receptors, Calcitonin / metabolism
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / genetics
  • Renal Insufficiency, Chronic / metabolism
  • Renal Insufficiency, Chronic / pathology
  • Signal Transduction / drug effects
  • Transfection
  • Up-Regulation
  • Vascular Calcification / genetics
  • Vascular Calcification / metabolism
  • Vascular Calcification / pathology
  • Vascular Calcification / prevention & control*

Substances

  • ADM2 protein, human
  • Peptide Hormones
  • Ramp3 protein, rat
  • Receptor Activity-Modifying Protein 3
  • Receptors, Calcitonin
  • Cholecalciferol
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Glucuronidase
  • Klotho Proteins